Panel Discussion: Streamlining or Impeding Clinical Success? Defining the Balance Between Precision Medicine & Patient Exclusion

Time: 12:00 pm
day: Day Two


  • How far should we be selecting patients that are fast progressors to streamline understanding of efficacy?
  • Segmenting patients in rare kidney diseases: how homogeneous does the patient population need to be in a small patient population?
  • Considering impact of precision medicine on commercial viability of drugs and ethical implications of excluding patients from trials